Clinical Trial

Pharmacokinetics and Pharmacodynamics Study

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-10.
Trial Details
NCT Number NCT07074236
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Enrollment 48 participants
Start Date 2025-07
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-24